{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally"
      ],
      "ArmGroupInterventionName": [
            "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
      ],
      "ArmGroupLabel": [
            "Intra-nasal infusion of MTF"
      ],
      "ArmGroupType": [
            "Other"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02192736"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) administered intra-nasally to 20 patients is a safe and useful procedure for inducing improvements in pulmonary function and quality of life in patients with asthma."
      ],
      "BriefTitle": [
            "Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "October 2020"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Asthma"
      ],
      "ConditionAncestorId": [
            "D000001982",
            "D000012140",
            "D000008173",
            "D000008171",
            "D000012130",
            "D000006969",
            "D000006967",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Bronchial Diseases",
            "Respiratory Tract Diseases",
            "Lung Diseases, Obstructive",
            "Lung Diseases",
            "Respiratory Hypersensitivity",
            "Hypersensitivity, Immediate",
            "Hypersensitivity",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC08",
            "BC20",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "Immune System Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Asthma"
      ],
      "ConditionBrowseLeafId": [
            "M3708",
            "M4410",
            "M14129",
            "M10322",
            "M10320",
            "M9170",
            "M14119",
            "M9172",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Asthma",
            "Bronchial Diseases",
            "Respiratory Tract Diseases",
            "Lung Diseases, Obstructive",
            "Lung Diseases",
            "Hypersensitivity",
            "Respiratory Hypersensitivity",
            "Hypersensitivity, Immediate",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000001249"
      ],
      "ConditionMeshTerm": [
            "Asthma"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The proposed study will assess primary safety and secondary efficacy endpoints of allogeneic UC-MSC-derived MTF administered to patients with asthma. Each patient will receive intra-nasal MTF once per week for a period of 4 weeks."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nSigned consent form by the subject\nMale or female\nBetween 18 and 65 years old and capability to comprehend this trial.\nAsthma diagnosed by a physician at least 1 year prior to study enrollment\nPoorly-controlled asthma at study enrollment. Poorly controlled asthma is defined as: chronic symptoms, episodic exacerbations, persistent and variable airways obstruction despite a continued requirement for short-acting beta 2-agonists despite the use of high doses of inhaled steroids.\nNonsmokers (stopped smoking at least 1 year ago) and limited life-time history of smoking (less than a 3 pack year history).\nBody mass index 19-40\nOn a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry or had to use a rescue dose during the last 4 weeks.\nFEV1 >50% predicted\n\nExclusion Criteria:\n\nPregnant or lactating women\nCognitively impaired adults\nSystemic steroids within the 4 weeks prior to enrollment\nNon-steroidal anti-inflammatory drugs (NSAIDs) for arthritis\nCurrent diagnosis of polyposis or sinusitis.\nInfection treated by antibiotics within the 4 weeks prior to enrollment\nImmunization within the 4 weeks prior to enrollment\nLung pathology other than asthma\nOther significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction <50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine >3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis\nIllicit drug use within the past year\nCurrent/active upper respiratory infection (URI) (if active URI, wait until asymptomatic for 1 week to enroll)\nAsthma exacerbation within the 4 weeks prior to enrollment (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)\nUndergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months prior to enrollment will be allowed to participate)\nClinically significant abnormalities present on screening 12-lead electrocardiogram\nWomen of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study\nParticipation in another clinical study within 4 weeks prior to enrollment\nSubject does not sign informed consent"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Intra-nasal infusion of MTF"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Trophic factors from umbilical cord mesenchymal stem cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "asthma",
            "umbilical cord",
            "mesenchymal",
            "stem cells",
            "trophic factors"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Active, not recruiting"
      ],
      "LastUpdatePostDate": [
            "June 26, 2018"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 25, 2018"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Translational Biosciences"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Panama City"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Panama"
      ],
      "LocationFacility": [
            "Punta Pacifica Hospital"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "21 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Translational Biosciences"
      ],
      "OrgStudyId": [
            "TBS-MTFAS-001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Punta Pacifia Hospital in Panama City, Panama"
      ],
      "OverallOfficialName": [
            "Moises Zebede, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "April 2020"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Evaluated 1 month after the final treatment"
      ],
      "PrimaryOutcomeMeasure": [
            "Number of patients with adverse events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "1 month"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "After first treatment\nAfter final treatment",
            "After first treatment\nAfter final treatment",
            "After first treatment\nAfter last treatment"
      ],
      "SecondaryOutcomeMeasure": [
            "Number of patients with a change in pulmonary function from baseline as measured by Forced Expiratory Volume (FEV1) following American Thoracic Society (ATS) guidelines",
            "Number of patients with a change in pulmonary function from baseline as measured by Forced Vital Capacity (FVC) following American Thoracic Society (ATS) guidelines",
            "Number of patients with a change in quality of life from baseline as measured by the University of Pittsburgh Medical Center (UPMC) Asthma Questionnaire"
      ],
      "SecondaryOutcomeTimeFrame": [
            "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month",
            "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 monrh",
            "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "July 2014"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "June 2018"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "July 17, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "July 14, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "July 15, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}